Use is recommended only if clearly needed and the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: B3
US FDA pregnancy category: C

Comment: Patients given this drug during labor and delivery should be monitored for hypertension and postpartum cerebral blood vessel ruptures.

Animal models have revealed evidence of cataract formation and decreased pup weight gain and survival when given maternally toxic doses given throughout gestation. There are no controlled data in human pregnancy.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Use has been associated with decreased prolactin levels in non-nursing women and in those with hyperprolactinemia; this drug may affect milk production during lactation.

Benefit should outweigh risk.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-The WHO considers this drug compatible with breastfeeding.
-The effects in the nursing infant are unknown.

See references